[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-dystonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-dystonia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,77,99,127,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100645305","noninvasive-brain-stimulation-for-cervical-dystonia-100645305",false,"NCT07681284","Noninvasive Brain Stimulation for Cervical Dystonia","The Effect of Noninvasive Brain Stimulation on Symptoms of Cervical Dystonia","NetworkStim","Inclusion Criteria\n\n* Aged between 18 and 85 years\n* Diagnosis of idiopathic cervical dystonia made by an expert physician\n* Last botulinum toxin injection administered at least two months before the start of participation in the study (Albanese, Abbruzzese et al. 2015)\n\nExclusion Criteria\n\n* Head or neck trauma occurring less than 12 months before the onset of dystonia\n* Acquired dystonia (e.g., drug-induced, brain lesions or trauma)\n* History of major psychiatric disorders (e.g., bipolar disorder, schizophrenia, obsessive-compulsive disorder)\n* History of neurological diseases other than CD (e.g., epilepsy, Parkinson's disease)\n* Other contraindications for TMS or brain MRI (e.g., metal in the head)\n* Pregnant or breastfeeding women\n* History of substance abuse or dependence","ALL","18 Years","85 Years",{"count":21,"type":22},26,"ESTIMATED","INTERVENTIONAL",[25],"NA","The primary aim of this study is to assess whether continuous theta-burst stimulation (cTBS) can be helpful in reducing symptoms of idiopathic cervical dystonia. This will be a parallel-group, randomised, sham-controlled, double blind clinical trial. Patients and investigators measuring patient symptoms clinical scales will be blinded from allocation group, investigators delivering the intervention will not be blinded, as this is not feasible. Real cTBS will be compared to sham cTBS, with patients allocated to these two groups with a 1:1 recruitment ratio.\n\nBilateral cTBS will be delivered four times daily, over eight days, for a total of 32 bilateral cTBS sessions. The primary outcome is the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS). This will be administered at T1 (pre-cTBS), T2 (day 10, following days 2-9 where patients received the intervention), T3 (2 weeks post the final session of cTBS), and T4 (4-5 weeks post the final session of cTBS).\n\nSecondary outcomes will be the TWSTRS subscales (severity, disability, pain), Quality of Life scale, Global dystonia severity rating scale (GDS), Fahn Tolosa Marin (FTM) modified (to include only questions relevant to head\u002Fneck tremor) tremor scale, kinematic data of patient's movement patterns, motor evoked potentials (MEPs), and resting-state fMRI data (fMRI).",[28],"Cervical Dystonia",[30,31,32,33],"Cervical dystonia","Transcranial magnetic stimulation","Somatosensory cortex","Continuous theta-burst stimulation","NOT_YET_RECRUITING","2026-06-26",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":22},"2026-07-06",{"date":42,"type":22},"2028-05-06",{"name":44,"class":45},"Fondazione Policlinico Universitario Campus Bio-Medico","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100611825","effect-of-vibro-tactile-stimulation-intensity-on-head-posture-in-cervical-dystonia-100611825","NCT07245615","Effect of Vibro-tactile Stimulation Intensity on Head Posture in Cervical Dystonia","The Effects of Different Vibro-tactile Stimulation Intensities on Head Posture in Cervical Dystonia","(CD-VTS)","Inclusion Criteria:\n\nConfirmed diagnosis of adult-onset, isolated idiopathic cervical dystonia.\n\nExclusion Criteria:\n\nHistory of other neurological diseases, including Parkinson's disease, essential tremor, dementia, etc.\n\nHistory of peripheral nervous system disease that can impair proprioception. Deep brain stimulation implanted or denervation surgery. UBACC score lower than 15. Severe head tremors or facial muscle contractions. Regular intake of benzodiazepines or antidepressant medication.",true,"30 Years",{"count":58,"type":22},50,[25],"The primary goal of this clinical trial is to examine the effects of cervical vibrotactile stimulation intensity on abnormal head posture in people with cervical dystonia. The main question is: Does higher vibration intensity correct head posture to a greater extent than lower vibration intensity? Researchers will compare the head posture of participants with cervical dystonia who receive different intensities of vibration to cervical muscles.\n\nThe secondary goal of this clinical trial is to examine the degree of proprioceptive impairment in cervical dystonia. Specifically, the study will assess proprioceptive impairment at the neck, wrist, and ankle joints, and seeks to determine whether the impairment improves with cervical vibrotactile stimulation.\n\nResearchers will compare the proprioception testing results of these joints between cervical dystonia patients and age- and sex- matched healthy controls. Researchers will also compare the neck proprioception testing results of cervical dystonia patients before and after stimulation.\n\nParticipants will visit the lab once for three hours, where they will go through:\n\n1. clinical questionnaires;\n2. neck, wrist, and ankle proprioception testing,\n3. vibrotactile stimulation where they sit and relax\n4. neck proprioception testing",[28],[63,64,65,66],"vibrotactile stimulation","non-invasive","symptom control","proprioception","RECRUITING","2026-06-09",{"date":70,"type":38},"2026-06-10",{"date":72,"type":38},"2025-03-10",{"date":74,"type":22},"2026-09-30",{"name":76,"class":45},"University of Minnesota",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100575364","phase-2-safety-and-effectiveness-of-valbenazine-as-adjunct-therapy-to-botulinum-toxin-injections-in-cervical-dystonia-100575364","NCT06771323","Safety and Effectiveness of Valbenazine as Adjunct Therapy to Botulinum Toxin Injections in Cervical Dystonia","Inclusion Criteria:\n\n* Idiopathic CD (neck musculature first and most prominently affected)\n* 18-75 years old (participants excluded if their dystonia symptoms began before age 18 as childhood-onset dystonia typically represents a genetic and\u002For primary generalized form of dystonia)\n* Onset of dystonia ≥18 years old, no known hyperkinetic movement disorder-related genetic mutation\n* Dystonia severity more than minimal and not very severe as defined by Toronto Western Spasmodic Torticollis Rating Scale-2 Motor Severity (TWSTRS-2-Severity) score ≥ 5 and ≤ 20.\n* Stable on botulinum toxin injections last 90 days (BoNT dose change \\\u003C10% and patient reported stability of response over last two injection cycles)\n* Stable on other neuroactive medications.\n\nExclusion Criteria:\n\n* History of deep brain stimulation\n* History of uncontrolled or untreated depression in the prior 3 months, suicidality, or history of suicide attempts\n* History of uncontrolled liver disease or failure\n* History of tardive dyskinesia or tardive dystonia\n* Currently taking dopaminergic and\u002For anti-dopaminergic medications including VMAT2 inhibitors or other antipsychotic medications\n* Exposure to dopaminergic and\u002For anti-dopaminergic medications including VMAT2 inhibitors or other antipsychotic medications in the last 30 days -Presence of parkinsonism or other movement disorder other than dystonia on exam -Receiving botulinum toxin injections at a planned frequency other than every 3 months or typically receive injections at intervals \\\u003C11 weeks or \\>13 weeks -Known history of long QT syndrome or cardiac tachyarrhythmia or any clinically significant cardiac abnormality.\n* Prolonged QTc as defined by \\> 450 msec for men and \\> 470 msec for women","75 Years",{"count":85,"type":22},20,[87],"PHASE2","The most common form of idiopathic dystonia is adult-onset cervical dystonia (CD), a focal form of dystonia affecting the muscles of the neck. CD is often associated with pain and limited range of motion, and frequently leads to reduced quality of life and disability. Effective long-term treatment options are extremely limited. Recurring botulinum neurotoxin (BoNT) injections can ease the symptoms of CD, but they frequently provide only partial relief and can be associated with intolerable side effects. Deep brain stimulation can be used to treat more severe cases of CD, but this neurosurgical procedure is invasive, on average only about 50% effective and may lead to serious adverse effects. Novel treatment approaches for CD are desperately needed to alleviate symptoms and improve the quality of life for the many who suffer from this chronic and disabling neurological disorder.",[28],"2026-06-03",{"date":92,"type":38},"2026-06-04",{"date":94,"type":38},"2024-12-17",{"date":96,"type":22},"2027-06",{"name":98,"class":45},"Virginia Commonwealth University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":46},"100603773","phase-2-zinc-as-an-adjunctive-therapy-for-cervical-dystonia-100603773","NCT07140874","Zinc as an Adjunctive Therapy for Cervical Dystonia","Evaluation of Supplemental Zinc as an Adjunct to Prolong the Duration of Benefit After Botulinum Toxin Injections in Subjects With Cervical Dystonia","Inclusion Criteria:\n\n* Adults aged 18-89 years.\n* Diagnosed with cervical dystonia.\n* Receiving regular BoNT type A (Botox) injections for at least six months.\n\nExclusion Criteria:\n\n* Known allergy or intolerance to zinc.\n* Significant comorbidities or concurrent medications that could interfere with study outcomes.\n* Pregnant or breastfeeding women.\n* Already taking a zinc supplement which would exceed tolerable upper intake level in adults (40 mg elemental zinc per day) with addition of zinc study supplement.","89 Years",{"count":108,"type":22},25,[87],"The goal of this clinical trial is to evaluate if supplemental zinc can prolong the duration of benefit of botulinum toxin injections in cervical dystonia patients receiving care at the University of Florida.\n\nThe main aims are:\n\n1. To evaluate the efficacy of zinc citrate supplementation in prolonging the duration of symptom relief provided by botulinum toxin type A (Botox) injections in cervical dystonia patients.\n2. To assess the safety and tolerability of zinc supplementation in this patient population.\n3. To analyze the potential influence of zinc supplementation on the quality of life and functional outcomes in cervical dystonia patients receiving Botox.\n\nResearchers will compare zinc citrate to a placebo (a look-alike substance that contains no active drug) to see if zinc works to extend the effects of Botox.\n\nParticipants will:\n\nTake zinc citrate or a placebo every day for 3 months, then cross over to the alternative treatment for another 3 months.\n\nVisit the clinic every 3 months for Botox injections, check ups and surveys.",[28],[113,114,115,116,117],"cervical dystonia","botulinum toxin","Botox","zinc citrate","zinc","2026-05-12",{"date":120,"type":38},"2026-05-15",{"date":122,"type":22},"2026-06-01",{"date":124,"type":22},"2027-05-31",{"name":126,"class":45},"University of Florida",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":151},"100588172","phase-2-a-study-of-ipn10200-for-the-treatment-of-cervical-dystonia-in-adults-100588172","NCT06937931","A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults","A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants","CATALPA","Inclusion Criteria:\n\n1. A clinical diagnosis of isolated Cervical Dystonia (CD) (idiopathic) characterized by dystonic symptoms localised to the head, neck, and shoulder areas with at least moderate severity at Screening and Baseline (Day 1) defined as:\n\n   * (a) Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score ≥20\n   * (b) TWSTRS-Severity subscale score ≥15\n   * (c) TWSTRS-Disability subscale score ≥3\n   * (d) TWSTRS-Pain subscale score ≥ 1\n2. Treatment naïve or non-naïve to BoNT therapy for CD\n\nExclusion Criteria:\n\n1. Participants presenting with a swallowing disorder of any origin which might be exacerbated by BoNT treatment, such as:\n\n   * (a) Grade 3 or 4 on the Dysphagia Severity Scale (severe dysphagia) with swallowing difficulties and requiring a change in diet.\n2. Predominant anterocollis.\n3. Predominant retrocollis.\n4. Traumatic torticollis or tardive torticollis.\n5. Marked limitation on passive range of motion that suggests cervical contractures or structural abnormality.","80 Years",{"count":137,"type":22},132,[87],"The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults.\n\nCD can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain and stiffness, and headaches. CD is believed to involve deep parts within the brain that control movement, but genetic factors, environmental factors, and abnormalities in the brain may also play a role.\n\nThe usual treatment for CD includes injecting BoNT into the affected muscles, but the treatment only lasts about 3 months. IPN10200 is designed to last for a longer period.\n\nThe study will consist of two periods:\n\n1. A Screening Period of up to 4 weeks (28 days) to assess whether a participant can take part in the study and requires at least one visit.\n2. A Treatment Period of 36 weeks.\n\nOn Day 1 of the treatment period, participants will receive either IPN10200 Dose A or Dose B (additional participants may receive IPN10200 Dose C) of the study drug, or placebo distributed into different muscles in the head, neck and shoulders. Participants may continue some other medications, but details need to be recorded.\n\nThere will be 10 visits to the clinic in person and one remote visits (phone call) (12 visits to the clinic for participants who receive Dose C). Participants will undergo blood samplings, urine collections, physical\u002Fneurological examinations, and clinical evaluations. Participants will also need to complete questionnaires throughout the study.\n\nThe total study duration for a participant will be up to 40 weeks (approximately 9 months).",[28],"2026-04-29",{"date":143,"type":38},"2026-05-05",{"date":145,"type":38},"2025-06-30",{"date":147,"type":22},"2027-11-05",{"name":149,"class":150},"Ipsen","INDUSTRY",44,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":164,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":46},"100494204","comparison-of-pallidal-with-subthalamic-deep-brain-stimulation-for-cervical-dystonia-100494204","NCT05715138","Comparison of Pallidal With Subthalamic Deep Brain Stimulation for Cervical Dystonia","A Randomized Controlled Trial Comparing PAllidal and SubThalamic Deep Brain Stimulation for Cervical Dystonia（the PASTS-CD Study）","Inclusion criteria\n\n1. Diagnosed as idiopathic or hereditary isolated CD;\n2. Severe functional impairment;\n3. Oral medication and injection of botulinum toxin become ineffective (\\> 3 months since last injection), or refuse to adopt botulinum toxin injection;\n4. No secondary causes of CD;\n5. Age 18-80 years old;\n6. Normal neurological examination except for dystonia;\n7. Normal brain MRI;\n8. The subject or their family members can fully understand the trial and sign the informed consent;\n9. Good compliance and willingness to receive regular follow-ups.\n\nExclusion criteria\n\n1. Diagnosed as secondary CD;\n2. CD with obvious trunk\u002Flimb involvement, or Meige syndrome;\n3. History of severe mental disorders, dementia, or epilepsy;\n4. Previous dystonia surgery (pallidotomy, thalamotomy, DBS, etc);\n5. Accompanied by other neurological diseases (Parkinson's disease, essential tremor, multiple sclerosis, stroke, etc);\n6. The patient has or needs other implantable devices (cardiac pacemakers, defibrillators, cochlear implants, spinal cord stimulators, etc);\n7. Pregnant women or women who are waiting to become pregnant during the trial;\n8. Poor health condition.",{"count":160,"type":22},98,[25],"Cervical dystonia (CD), also known as spasmodic torticollis, is a type of focal dystonia, mainly manifesting as involuntary head turning or tilting, or holding a twisted posture. Although it can be alleviated by injection of botulinum toxin, the effect is temporary so that patients require multiple injections. Deep Brain Stimulation (DBS) targeting on globus pallidus internus (GPi) or subthalamic nucleus (STN) has been proved to be a safe and effective strategy for primary cervical dystonia, even for those medically refractory cases. However, the question of which target is better has not been clarified.\n\nTherefore, the invstigators design this randomized and controlled trial, aiming to compare the differences between GPi-DBS and STN-DBS for cervical dystonia in the improvement of symptoms , quality of life, mental status, cognitive status, as well as in stimulation parameters and adverse effects. The invstigators hypothesize that STN-DBS will outperform GPi-DBS at short-term follow-up, while the superiority will disappear and the efficacy of the two group will become similar at long-term follow-up.",[28],[165,166,167],"globus pallidus internus","subthalamic nucleus","deep brain stimulation","2023-07-19",{"date":170,"type":38},"2023-07-21",{"date":172,"type":22},"2023-09-01",{"date":174,"type":22},"2026-11-30",{"name":176,"class":45},"Chinese PLA General Hospital"]